The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01.
L. Nayak
No relevant relationships to disclose
L. E. Abrey
Consultant or Advisory Role - Roche
J. Drappatz
No relevant relationships to disclose
M. R. Gilbert
Consultant or Advisory Role - Genentech; Sigma-Tau
Honoraria - Genentech; Merck; Sigma-Tau
Research Funding - Genentech; Merck
D. A. Reardon
No relevant relationships to disclose
K. Lamborn
No relevant relationships to disclose
P. Y. Wen
Research Funding - Merck
M. Prados
No relevant relationships to disclose
L. M. DeAngelis
Consultant or Advisory Role - Genentech
A. M. P. Omuro
Research Funding - Genentech; Schering-Plough